Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Fowler Website

Daniel H. Fowler, M.D.

Selected Publications

1)  Felizardo TC, Foley J, Steed K, Dropulic B, Amarnath S, Medin JA, Fowler DH.
Harnessing autophagy for cell fate control gene therapy.
Autophagy. 9: 1069-79, 2013.
2)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
3)  Castiello L, Mossoba M, Viterbo A, Sabatino M, Fellowes V, Foley JE, Winterton M, Halverson DC, Civini S, Jin P, Fowler DH, Stroncek DF.
Differential gene expression profile of first-generation and second-generation rapamycin-resistant allogeneic T cells.
Cytotherapy. 15: 598-609, 2013.
4)  Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, Williams KM, Datiles MB, Bishop R, Bassim CW, Mays JW, Edwards D, Cole K, Avila DN, Taylor T, Urban A, Joe GO, Comis LE, Berger A, Stratton P, Zhang D, Shelhamer JH, Gea-Banacloche JC, Sportes C, Fowler DH, Gress RE, Pavletic SZ.
National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis.
Biol. Blood Marrow Transplant. 19: 632-9, 2013.
5)  Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR.
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
Bone Marrow Transplant. 48: 269-77, 2013.
6)  Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR.
Phase II clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
Blood. [Epub ahead of print], 2013.
7)  Pavletic SZ, Fowler DH.
Are we making progress in GVHD prophylaxis and treatment?.
Hematology Am Soc Hematol Educ Program. 2012: 251-64, 2012.
8)  Neschadim A, Wang JC, Sato T, Fowler DH, Lavie A, Medin JA.
Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.
Mol. Ther. 20: 1002-13, 2012.
9)  Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW, Mitchell SA, Hakim FT, Martires KJ, Avila DN, Taylor TN, Salit RB, Rowley SD, Zhang D, Fowler DH, Bishop MR, Gress RE, Pavletic SZ.
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.
Leukemia. 26: 633-43, 2012.
10)  Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR.
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Blood. 119: 2956-9, 2012.
11)  Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR.
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
J. Clin. Oncol. 30: 830-6, 2012.
12)  Fowler DH.
Editorial: protean effects of IL-10 include skin self-defense.
J. Leukoc. Biol. 92: 247-8, 2012.
13)  Scaife M, Pacienza N, Au BC, Wang JC, Devine S, Scheid E, Lee C, Lopez-Perez O, Neschadim A, Fowler DH, Foley R, Medin JA.
Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes.
Gene Ther. [Epub ahead of print], 2012.
14)  Amarnath S, Fowler DH.
Harnessing autophagy for adoptive T-cell therapy.
Immunotherapy. 4: 1-4, 2012.
15)  Miller TW, Wang EA, Gould S, Stein EV, Kaur S, Lim L, Amarnath S, Fowler DH, Roberts DD.
Hydrogen sulfide is an endogenous potentiator of T cell activation.
J. Biol. Chem. 287: 4211-21, 2012.
16)  Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, Humphrey JL, Rager A, Richards K, Wayne AS, Mackall CL.
Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.
Biol. Blood Marrow Transplant. 18: 698-707, 2012.
17)  Laurence A, Amarnath S, Mariotti J, Kim YC, Foley J, Eckhaus M, O'Shea JJ, Fowler DH.
STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease.
Immunity. 37: 209-22, 2012.
18)  Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A.
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Bone Marrow Transplant. [Epub ahead of print], 2012.
19)  Felizardo TC, Wang JC, McGray RA, Evelegh C, Spaner DE, Fowler DH, Bramson JL, Medin JA.
Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model.
Gene Ther. [Epub ahead of print], 2011.
20)  Amarnath S, Chen H, Foley JE, Costanzo CM, Sennesh JD, Solomon MA, Fowler DH.
Host-based th2 cell therapy for prolongation of cardiac allograft viability.
PLoS ONE. 6: e18885, 2011.
21)  Mossoba ME, Onda M, Taylor J, Massey PR, Treadwell S, Sharon E, Hassan R, Pastan I, Fowler DH.
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
Clin. Cancer Res. 17: 3697-705, 2011.
22)  Hardy NM, Mossoba ME, Steinberg SM, Fellowes V, Yan XY, Hakim FT, Babb RR, Avila D, Gea-Banacloche J, Sportès C, Levine BL, June CH, Khuu HM, Carpenter AE, Krumlauf MC, Dwyer AJ, Gress RE, Fowler DH, Bishop MR.
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.
Clin. Cancer Res. 17: 6878-87, 2011.
23)  Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, Levine BL, June CH, Medin JA, Fowler DH.
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
Sci Transl Med. 3: 111ra120, 2011.
24)  Mariotti J, Taylor J, Massey PR, Ryan K, Foley J, Buxhoeveden N, Felizardo TC, Amarnath S, Mossoba ME, Fowler DH.
The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.
Biol. Blood Marrow Transplant. 17: 620-31, 2011.
25)  Jamshed S, Fowler DH, Neelapu SS, Dean RM, Steinberg SM, Odom J, Bryant K, Hakim F, Bishop MR.
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Bone Marrow Transplant. [Epub ahead of print], 2010.
In Press. [Journal]
26)  Bishop MR, Dean RM, Steinberg SM, Odom J, Pollack SM, Pavletic SZ, Sportes C, Gress RE, Fowler DH.
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Cancer. 116: 852-62, 2010.
27)  Mitchell SA, Leidy NK, Mooney KH, Dudley WN, Beck SL, LaStayo PC, Cowen EW, Palit P, Comis LE, Krumlauf MC, Avila DN, Atlam N, Fowler DH, Pavletic SZ.
Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD).
Bone Marrow Transplant. 45: 762-9, 2010.
28)  Amarnath S, Flomerfelt FA, Costanzo CM, Foley JE, Mariotti J, Konecki DM, Gangopadhyay A, Eckhaus M, Wong S, Levine BL, June CH, Fowler DH.
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.
Autophagy. 6, 2010.
29)  Amarnath S, Costanzo CM, Mariotti J, Ullman JL, Telford WG, Kapoor V, Riley JL, Levine BL, June CH, Fong T, Warner NL, Fowler DH.
Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1.
PLoS Biol. 8: e1000302, 2010.
30)  Granville CA, Memmott RM, Balogh A, Mariotti J, Kawabata S, Han W, Lopiccolo J, Foley J, Liewehr DJ, Steinberg SM, Fowler DH, Hollander MC, Dennis PA.
A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis.
PLoS ONE. 4: e5061, 2009.
31)  Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, Bishop MR.
Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
Biol. Blood Marrow Transplant. 15: 223-30, 2009.
32)  Fowler D, Hoffmann P, Edinger M.
Functionally defined T cell subsets in transplantation biology and therapy: regulatory T cells and Th2 cells.
Cancer Treat. Res. 144: 155-86, 2009.
33)  Scaife MD, Neschadim A, Fowler DH, Medin JA.
Novel application of lentiviral vectors towards treatment of graft-versus-host disease.
Expert Opin Biol Ther. 9: 749-61, 2009.
34)  Loisel-Meyer S, Felizardo T, Mariotti J, Mossoba ME, Foley JE, Kammerer R, Mizue N, Keefe R, McCart JA, Zimmermann W, Dropulic B, Fowler DH, Medin JA.
Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection.
Mol. Cancer Ther. 8: 692-702, 2009.
35)  Symes JC, Siatskas C, Fowler DH, Medin JA.
Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.
Cancer Gene Ther. 16: 439-52, 2009.
36)  Sportès C, Steinberg SM, Liewehr DJ, Gea-Banacloche J, Danforth DN, Avila DN, Bryant KE, Krumlauf MC, Fowler DH, Pavletic S, Hardy NM, Bishop MR, Gress RE.
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy.
Biol. Blood Marrow Transplant. 15: 963-70, 2009.
37)  Fowler D.
T cells helping GVHD: take-away lessons.
Blood. 114: 2858-9, 2009.
38)  Koh C, Kleiner DE, Sherry RM, Fowler DH, Heller T.
When the left got left behind.
Am. J. Gastroenterol. 104: 2644-5, 2009.
39)  Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.
Ann Oncol. 19: 1935-40, 2008.
40)  Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, Fowler DH, Bishop MR, Kang EM, Malech HL, Dunbar CE, Khuu HM, Wesley R, Yau YY, Bolan CD.
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.
Blood. 112: 2092-100, 2008.
41)  Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, Han S, Hanson JT, Wong E, Buxhoeveden N, Trepel JB, Fojo AT, Telford W, Fowler DH.
Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection.
J. Immunol. 180: 89-105, 2008.
42)  Mariotti J, Foley J, Ryan K, Buxhoeveden N, Kapoor V, Amarnath S, Fowler DH.
Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an IL-4/STAT6 pathway.
Blood. 112: 4765-75, 2008.
43)  Svirshchevskaya EV, Mariotti J, Wright MH, Viskova NY, Telford W, Fowler DH, Varticovski L.
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.
BMC Cancer. 8: 176, 2008.
44)  Pavletic SZ, Fowler DH.
Regulating rheumatoid arthritis via autotransplantation.
Blood. 111: 4838-9, 2008.
45)  Foley JE, Mariotti J, Ryan K, Eckhaus M, Fowler DH.
Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells.
Biol. Blood Marrow Transplant. 14: 959-72, 2008.
46)  Mossoba ME, Walia JS, Rasaiah VI, Buxhoeveden N, Head R, Ying C, Foley JE, Bramson JL, Fowler DH, Medin JA.
Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.
Mol. Ther. 16: 607-17, 2008.
47)  Imanguli MM, Atkinson JC, Harvey KE, Hoehn GT, Ryu OH, Wu T, Kingman A, Barrett AJ, Bishop MR, Childs RW, Fowler DH, Pavletic SZ, Hart TC.
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.
Exp. Hematol. 35: 184-92, 2007.
48)  Subramaniam DS, Fowler DH, Pavletic SZ.
Chronic graft-versus-host disease in the era of reduced-intensity conditioning.
Leukemia. 21: 853-9, 2007.
49)  Snyder JT, Shen J, Azmi H, Hou J, Fowler DH, Ragheb JA.
Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production.
Blood. 109: 5399-406, 2007.
50)  Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA.
Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy.
Mol. Ther. 15: 962-70, 2007.
51)  Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R, Odom J, Fowler DH, Gress RE, Bishop MR.
Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.
Biol. Blood Marrow Transplant. 13: 1022-30, 2007.
52)  Liang SB, Yoshimitsu M, Poeppl A, Rasaiah VI, Cai J, Fowler DH, Medin JA.
Multiple Reduced-intensity Conditioning Regimens Facilitate Correction of Fabry Mice After Transplantation of Transduced Cells.
Mol. Ther. 15: 618-27, 2007.
53)  Jung U, Foley JE, Erdmann AA, Toda Y, Borenstein T, Mariotti J, Fowler DH.
Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Biol. Blood Marrow Transplant. 12: 905-18, 2006.
54)  Hardy NM, Fowler DH, Bishop MR.
Immunotherapy of metastatic breast cancer: phase I trail of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange.
Clin. Breast Cancer. 7: 87-9, 2006.
55)  Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR.
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant. 12: 1150-60, 2006.
56)  Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ.
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.
Biol. Blood Marrow Transplant. 12: 126-37, 2006.
57)  Yamashita K, Horwitz ME, Kwatemaa A, Nomicos E, Castro K, Sokolic R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne AS, Fowler DH, Bishop MR, Childs RW, Barrett AJ, Pavletic SZ, Malech HL.
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
Biol. Blood Marrow Transplant. 12: 22-30, 2006.
58)  Erdmann AA, Gao ZG, Jung U, Foley J, Borenstein T, Jacobson KA, Fowler DH.
Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.
Blood. 105: 4707-14, 2005.
59)  Fowler D, Gress R.
Allogeneic graft-versus-tumor effects: Mechanistic insights and therapeutic promise.
Drug Discovery Today: Disease Mechanisms. 2: 205-212, 2005.
60)  Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C, Kasten-Sportes C, Gress RE, Bishop MR.
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma.
Biol Blood Marrow Transplant. 11: 593-9, 2005.
61)  Medin JA, Liang SB, Hou JW, Kelley LS, Peace DJ, Fowler DH.
Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Cancer Gene Ther. 12: 540-51, 2005.
62)  Sportes C, McCarthy NJ, Hakim F, Steinberg SM, Liewehr DJ, Weng D, Kummar S, Gea-Banacloche J, Chow CK, Dean RM, Castro KM, Marchigiani D, Bishop MR, Fowler DH, Gress RE.
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.
Biol Blood Marrow Transplant. 11: 472-83, 2005.
63)  Foley JE, Jung U, Miera A, Borenstein T, Mariotti J, Eckhaus M, Bierer BE, Fowler DH.
Ex vivo rapamycin generates donor Th2 cells that potently inhibit GVHD and GVT effects via an IL-4 dependent mechanism.
J Immunol. 175: 5732-5743, 2005.
64)  Fowler D, Gress R.
In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation.
Current Medicinal Chemistry-Immunology, Endocrine, and Metabolic Agents. 5: 555-564, 2005.
65)  Fowler DH.
Shared Biology of GVHD and GVT Effects: Potential Methods of Separation.
Crit Rev Oncol Hematol. 57: 225-244, 2005.
66)  Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R.
Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
J Clin Oncol. 22: 3886-92, 2004.
67)  Fowler DH, Foley J, Whit-Shan Hou J, Odom J, Castro K, Steinberg SM, Gea-Banacloche J, Kasten-Sportes C, Gress RE, Bishop MR.
Clinical 'cytokine storm' as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease.
Clin Gastroenterol Hepatol. 2: 237-245, 2004.
68)  Erdmann AA, Jung U, Foley JE, Toda Y, Fowler DH.
Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Biol Blood Marrow Transplant. 10: 604-13, 2004.
69)  Fowler D, Bishop M, Gress R.
Immunoablative RIST: Potential Role of Donor Th2 and Tc2 Cells.
Seminars in Oncology. 31(1): 56-67, 2004.
70)  Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Gea-Banacloche J, Castro K, Hakim F, Krumlauf M, Read EJ, Carter C, Leitman SF, Fowler DH.
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
Br J Haematol. 126: 837-43, 2004.
71)  Jung U, Foley JE, Erdmann AA, Eckhaus MA, Fowler DH.
CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects.
Blood. 102: 3439-46, 2003.
72)  Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH.
Establishment of Early Donor Engraftment after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation to Potentiate the Graft-versus-Lymphoma Effect against Refractory Lymphomas.
Biol Blood Marrow Transplant. 9: 162-169, 2003.
73)  Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL.
Interleukin-7 worsens graft-vs-host disease.
Blood. 4: 1082, 2002.
74)  Fowler D, Hou J, Foley J, Hakim F, Odom J, Castro K, Carter C, Read E, Gea-Benacloche J, Kasten-Sportes C, Kwak L, Wilson W, Levine B, June C, Gress R, Bishop M.
Phase I Clinical of Donor Th2 Cells after Immunoablative, Reduced Intensity Allogeneic PBSCT.
Cytotherapy. Vol. 4 (5): 429-430, 2002.
75)  Medin JA, Fowler DH.
Post-Transduction Events in Retrovirus-Mediated Gene Transfer Involving Hematopoietic Stem Cells: Beyond Efficiency Issues.
J Cell Biochem Suppl. 38: 46-54, 2002.
Click Here to View Collapsed Bibliography.

This page was last updated on 11/21/2013.